{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:44Z","timestamp":1792784924955,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"BeOne Medicines Ltd","id":[{"id":"https:\/\/ror.org\/03saz3d95","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77705-8","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:17:22Z","timestamp":1789748242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7668-9674","authenticated-orcid":false,"given":"Feng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hsien","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8683-6145","authenticated-orcid":false,"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-5653","authenticated-orcid":false,"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunee","family":"Dechaphunkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiting","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"77705_CR1","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","volume":"69","author":"M Arnold","year":"2020","unstructured":"Arnold, M., Ferlay, J., van Berge Henegouwen, M. I. & Soerjomataram, I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut 69, 1564\u20131571 (2020).","journal-title":"Gut"},{"key":"77705_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1254","volume":"11","author":"EO Then","year":"2020","unstructured":"Then, E. O. et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J. Oncol. 11, 55\u201364 (2020).","journal-title":"World J. Oncol."},{"key":"77705_CR3","doi-asserted-by":"publisher","first-page":"104134","DOI":"10.1016\/j.esmoop.2025.104134","volume":"10","author":"RL Obermannov\u00e1","year":"2025","unstructured":"Obermannov\u00e1, R. L. & Leong, T. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. ESMO Open 10, 104134 (2025).","journal-title":"ESMO Open"},{"key":"77705_CR4","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","volume":"404","author":"H Yang","year":"2024","unstructured":"Yang, H., Wang, F., Hallemeier, C. L., Lerut, T. & Fu, J. Oesophageal cancer. Lancet 404, 1991\u20132005 (2024).","journal-title":"Lancet"},{"key":"77705_CR5","unstructured":"Bristol Myers Squibb Company. OPDIVO Prescribing Information. https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf (BMS, 2025)."},{"key":"77705_CR6","unstructured":"Merck & Co. Inc. KEYTRUDA Prescribing Information. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf (MERCK, 2025)."},{"key":"77705_CR7","unstructured":"BeiGene USA Inc. TEVIMBRA Prescribing Information. https:\/\/www.beigene.com\/PDF\/TEVIMBRAUSPI.pdf (BEIGENE, 2025)."},{"key":"77705_CR8","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO-24-01818","volume":"43","author":"Z Lu","year":"2025","unstructured":"Lu, Z. et al. NOTCH1 mutation and survival analysis of tislelizumab in advanced or metastatic esophageal squamous cell carcinoma: a biomarker analysis from the randomized, Phase III, RATIONALE-302 Trial. J. Clin. Oncol. 43, 1898\u20131909 (2025).","journal-title":"J. Clin. Oncol."},{"key":"77705_CR9","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima, T. et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 38, 4138\u20134148 (2020).","journal-title":"J. Clin. Oncol."},{"key":"77705_CR10","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato, K. et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 1506\u20131517 (2019).","journal-title":"Lancet Oncol."},{"key":"77705_CR11","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen, L. et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized Phase III study. J. Clin. Oncol. 40, 3065\u20133076 (2022).","journal-title":"J. Clin. Oncol."},{"key":"77705_CR12","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.3389\/fimmu.2018.02821","volume":"9","author":"XM Zhou","year":"2018","unstructured":"Zhou, X. M. et al. Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8(+) T cells. Front Immunol. 9, 2821 (2018).","journal-title":"Front Immunol."},{"key":"77705_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4, H. & Guillerey, C. TIGIT as an emerging immune checkpoint. Clin. Exp. Immunol. 200, 108\u2013119 (2020).","journal-title":"Clin. Exp. Immunol."},{"key":"77705_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"KL Banta","year":"2022","unstructured":"Banta, K. L. et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity 55, 512\u2013526.e519 (2022).","journal-title":"Immunity"},{"key":"77705_CR15","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1172\/JCI80445","volume":"125","author":"JM Chauvin","year":"2015","unstructured":"Chauvin, J. M. et al. TIGIT and PD-1 impair tumor antigen-specific CD8\u207a T cells in melanoma patients. J. Clin. Invest 125, 2046\u20132058 (2015).","journal-title":"J. Clin. Invest"},{"key":"77705_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu, X., Tian, W., Wang, Z., Zhang, J. & Zhou, R. Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: Mechanisms and clinical trials. Mol. Cancer 22, 93 (2023).","journal-title":"Mol. Cancer"},{"key":"77705_CR17","doi-asserted-by":"crossref","unstructured":"Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169\u2013175 (2017).","DOI":"10.1038\/nature20805"},{"key":"77705_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang, P. et al. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark. Res. 12, 7 (2024).","journal-title":"Biomark. Res."},{"key":"77705_CR19","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1097\/AS9.0000000000000385","volume":"5","author":"Y Nagaki","year":"2024","unstructured":"Nagaki, Y. et al. Neoadjuvant chemoradiotherapy upregulates the immunogenicity of cold to hot tumors in esophageal cancer patients. Ann. Surg. Open 5, e385 (2024).","journal-title":"Ann. Surg. Open"},{"key":"77705_CR20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ccell.2023.03.016","volume":"41","author":"YX Chen","year":"2023","unstructured":"Chen, Y. X. et al. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Cancer Cell 41, 919\u2013932.e915 (2023).","journal-title":"Cancer Cell"},{"key":"77705_CR21","doi-asserted-by":"publisher","first-page":"S635","DOI":"10.1016\/j.jtho.2021.01.1160","volume":"16","author":"N Patil","year":"2021","unstructured":"Patil, N. et al. P77.02 Efficacy of tiragolumab + atezolizumab in PD-L1 IHC and TIGIT subgroups in the Phase II CITYSCAPE study in first-line NSCLC. J. Thorac. Oncol. 16, S635\u2013S636 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"77705_CR22","first-page":"245","volume":"42","author":"C-H Hsu","year":"2024","unstructured":"Hsu, C.-H. et al. SKYSCRAPER-08: a phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC). J Clin. Oncol 42, 245 (2024).","journal-title":"Oncol"},{"key":"77705_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.2024.42.3_suppl.324","volume":"42","author":"J-M Sun","year":"2024","unstructured":"Sun, J.-M. et al. MORPHEUS-EC: a phase Ib\/II open-label, randomized study of first-line tiragolumab (tira) + atezolizumab (atezo) + chemotherapy (CT) in patients (pts) with esophageal cancer (EC). J. Clin. Oncol 42, 324 (2024).","journal-title":"J. Clin. Oncol"},{"key":"77705_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan, X. et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells. Nature 627, 646\u2013655 (2024).","journal-title":"Nature"},{"key":"77705_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.828319","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. An Fc-competent anti-human TIGIT blocking antibody ociperlimab (BGB-A1217) elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models. Front. Immunol. 13, 828319 (2022).","journal-title":"Front. Immunol."},{"key":"77705_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"77705_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13000-023-01318-8","volume":"18","author":"C Liu","year":"2023","unstructured":"Liu, C., Fang, F., Kong, Y. & ElGabry, E. A. Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. Diagn. Pathol. 18, 48 (2023).","journal-title":"Diagn. Pathol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77705-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77705-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77705-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:29:02Z","timestamp":1792535342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77705-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77705"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77705-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S. reports research funding from Yuhan. D.T. reports consulting or advisory roles for Amgen, AstraZeneca, INCYTE, MSD, Merck Serono, BMS, Novartis, Pierre Fabre, Roche, Servier, Gilead, Takeda, GSK, BeOne Medicines, and Taiho; and research funding from Pierre Fabre and Sandoz. S.K. reports consulting or advisory roles for AstraZeneca, Lilly, DaeHwa Pharmaceutical Co., Ltd. ISU Abix, BeOne Medicines, OBI Pharma, Ensol Biosciences, LegoChem Biosciences, Kalbe Pharma and Daichi-Sankyo; stock and other ownership interests in Genopeaks; and research funding from Genzyme. E.V.C. reports consulting or advisory role for AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas, AstraZeneca, Bayer, BeOne Medicines, Bexon Clinical, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Canfour, Daiichi Sankyo, Debiopharm, Elmedix, Eisai, Galapagos, GSK, Hookipa Biotech, INCYTE, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seattle Genetics, Servier, Simcere, Takeda, Taiho Pharmaceutical, and Terumo. A.Z. reports consulting or advisory roles for Amgen, Merck Serono, Sanofi, MSD, Servier, Astellas Pharma, BMS GmbH & Co. KG, Pierre Fabre, AstraZeneca, Daiichi Sankyo, BeOne Medicines, AbbVie, Gilead Sciences, and Jazz Pharmaceuticals; support for travel, accommodation, expenses: Servier, MSD, Pierre Fabre, Amgen, Merck, Jazz Pharmaceuticals, and Astellas Pharmaceutical; and research funding from Amgen. F.R. reports consulting or advisory role for Amgen, Astellas Pharma, AstraZeneca Spain, BMSi, and MSD; honoraria from BMSi, MSD, and Servier; support for travel, accommodation, and expenses from MSD; research funding from MSD. Y.Z., Q.W., Juan Z., and J. Zhou report employment with BeOne Medicines. R.X. reports consulting or advisory roles for Bristol-Myers Squibb, Merck Serono, Roche, Astellas, AstraZeneca, Junshi, Hengrui, BeOne Medicines, and CRPC. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10964"}}